2017
DOI: 10.1016/j.jtho.2017.09.869
|View full text |Cite
|
Sign up to set email alerts
|

P1.04-010 CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…A total of 21 studies reported ORR data [ 4 , 6 9 , 11 14 , 16 , 18 28 ], involving 815 uninfected patients and 1,061 hepatitis patients. This meta-analysis showed ( Figure 2 ) that the pooled ORR of uninfected patients, HCV patients, and HBV patients was 18.10% (95% CI: 12.00%–25.00%), 23.95% (95% CI: 16.36%–32.28%), and 26.49% (95% CI: 21.12%–32.19%), respectively.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…A total of 21 studies reported ORR data [ 4 , 6 9 , 11 14 , 16 , 18 28 ], involving 815 uninfected patients and 1,061 hepatitis patients. This meta-analysis showed ( Figure 2 ) that the pooled ORR of uninfected patients, HCV patients, and HBV patients was 18.10% (95% CI: 12.00%–25.00%), 23.95% (95% CI: 16.36%–32.28%), and 26.49% (95% CI: 21.12%–32.19%), respectively.…”
Section: Resultsmentioning
confidence: 99%
“…Median progression-free survival (mPFS) was published by 11 studies [8,9,12,15,17,19,20,[22][23][24]27]. Te pooled mPFS (Figure 4) was 5.01 months (95% CI: 4.05-5.97) for uninfected patients, 5.72 months (95% CI: 2.29-9.15) for patients with HCV, and 4.39 months (95% CI: 2.12-6.66) for patients with HBV.…”
Section: Mpfsmentioning
confidence: 99%